Enoxaparin: a pharmacoeconomic review of its use in the prevention and treatment of venous thromboembolism and in acute coronary syndromes (Q34597851)

3 August 2017

title

Enoxaparin: a pharmacoeconomic review of its use in the prevention and treatment of venous thromboembolism and in acute coronary syndromes (English)

1 reference

3 August 2017

main subject

venous thromboembolism

1 reference

inferred from title

acute coronary syndrome

1 reference

David Bergqvist

1

1 reference

3 August 2017

publication date

1 January 2002

1 reference

3 August 2017

1 reference

3 August 2017

volume

20

1 reference

3 August 2017

issue

4

1 reference

3 August 2017

page(s)

225-243

1 reference

Cost analysis of ardeparin versus enoxaparin for the prophylaxis of deep vein thrombosis after knee arthroplasty

3 August 2017

cites work

1 reference

12 December 2020

Managed care: the US experience.

1 reference

12 December 2020

Pulmonary embolism and its prophylaxis following the Charnley total hip replacement

1 reference

12 December 2020

An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study

1 reference

12 December 2020

New antithrombotic agents

1 reference

12 December 2020

Warfarin vs enoxaparin for deep venous thrombosis prophylaxis after total hip & total knee arthroplasty: a cost comparison

1 reference

12 December 2020

Subcutaneous heparin versus low-molecular-weight heparin as thromboprophylaxis in patients undergoing colorectal surgery: results of the canadian colorectal DVT prophylaxis trial: a randomized, double-blind trial

1 reference

12 December 2020

Prevention of deep-vein thrombosis following total hip replacement surgery with enoxaparin versus unfractionated heparin: a pharmacoeconomic evaluation

1 reference

12 December 2020

Economic evaluation of standard heparin and enoxaparin for prophylaxis against deep vein thrombosis in elective hip surgery

1 reference

12 December 2020

Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis

1 reference

12 December 2020

Will the use of low-molecular-weight heparin (enoxaparin) in patients with acute coronary syndrome save costs in Canada?

1 reference

12 December 2020

Pharmacy-managed program for home treatment of deep vein thrombosis with enoxaparin

1 reference

12 December 2020

Cost-effectiveness of enoxaparin versus low-dose heparin for prophylaxis against venous thrombosis after major trauma

1 reference

12 December 2020

Use of low molecular weight heparin in preventing thromboembolism in trauma patients

1 reference

12 December 2020

Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Even

1 reference

12 December 2020

The emerging role of low-molecular-weight heparin and antiplatelet therapies in the cardiac catheterization laboratory

1 reference

12 December 2020

Economic evaluation of enoxaparin vs. placebo for the prevention of venous thromboembolism in acutely ill medical patients

1 reference

12 December 2020

A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma

1 reference

12 December 2020

Prophylaxis of postoperative thromboembolism with low molecular weight heparins.

1 reference

12 December 2020

Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis

1 reference

12 December 2020

Cost-effectiveness of low-molecular-weight heparin and unfractionated heparin in treatment of deep vein thrombosis

1 reference

12 December 2020

Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis

1 reference

12 December 2020

Primer on medical decision analysis: Part 1--Getting started.

1 reference

12 December 2020

Economic evaluation of outpatient treatment with low-molecular-weight heparin for proximal vein thrombosis

1 reference

12 December 2020

Low-molecular-weight heparins

1 reference

12 December 2020

Variations between countries in invasive cardiac procedures and outcomes in patients with suspected unstable angina or myocardial infarction without initial ST elevation. OASIS (Organisation to Assess Strategies for Ischaemic Syndromes) Registry Inv

1 reference

12 December 2020

A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group

1 reference

12 December 2020

Prevention of deep vein thrombosis after elective hip surgery. A randomized trial comparing low molecular weight heparin with standard unfractionated heparin

1 reference

12 December 2020

Out-of-hospital treatment of venous thrombosis: socioeconomic aspects and patients' quality of life

1 reference

12 December 2020

Cost effectiveness of low-molecular weight heparin versus warfarin following hip replacement surgery.

1 reference

12 December 2020

Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomised comparison of enoxaparin versus placebo

1 reference

12 December 2020

Prevention of postoperative venous thrombosis: a randomized trial comparing unfractionated heparin with low molecular weight heparin in patients undergoing total hip replacement

1 reference

12 December 2020

Use of enoxaparin, a low-molecular-weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement. A clinical trial comparing efficacy and safety. Enoxaparin Clinical Trial Group.

1 reference

12 December 2020

A clinical trial of a chest-pain observation unit for patients with unstable angina. Chest Pain Evaluation in the Emergency Room (CHEER) Investigators

1 reference

12 December 2020

Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin

1 reference

12 December 2020

Cost of Long-Term Complications of Deep Venous Thrombosis of the Lower Extremities: An Analysis of a Defined Patient Population in Sweden

1 reference

12 December 2020

Prolonged thromboprophylaxis following hip replacement surgery--results of a double-blind, prospective, randomised, placebo-controlled study with dalteparin (Fragmin)

1 reference

12 December 2020

Healthcare resource utilisation and costs of treating NSAID-associated gastrointestinal toxicity. A multinational perspective

1 reference

12 December 2020

Managing the risk of thrombosis in the perioperative period in patients undergoing orthopedic and trauma surgery with low-molecular-weight heparin: enoxaparin

1 reference

12 December 2020

A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis

1 reference

12 December 2020

Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement

1 reference

12 December 2020

Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients: a double-blind, randomized comparison. North American Fragmin Trial Investigators

1 reference

12 December 2020

A pharmacoeconomic assessment of enoxaparin and warfarin as prophylaxis for deep vein thrombosis in patients undergoing knee replacement surgery

1 reference

12 December 2020

Cost for inpatient care of venous thrombosis: a trial of enoxaparin vs standard heparin

1 reference

12 December 2020

In pursuit of quality: the National Institute for Clinical Excellence

1 reference

12 December 2020

Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes

1 reference

12 December 2020

A Comparison of Enoxaparin with Placebo for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients

1 reference

12 December 2020

The economic impact of treating deep vein thrombosis with low-molecular-weight heparin: outcome of therapy and health economy aspects

1 reference

12 December 2020

The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups

1 reference

12 December 2020

Prevention of venous thromboembolism after knee arthroplasty. A randomized, double-blind trial comparing enoxaparin with warfarin.

1 reference

12 December 2020

Effectiveness and economic impact associated with a program for outpatient management of acute deep vein thrombosis in a group model health maintenance organization

1 reference

12 December 2020

Cost-effectiveness of enoxaparin vs low-dose warfarin in the prevention of deep-vein thrombosis after total hip replacement surgery.

1 reference

12 December 2020

Fixed low-dose versus adjusted higher-dose warfarin following orthopedic surgery. A randomized prospective trial

1 reference

12 December 2020

Deep venous thrombosis: a continuing problem

1 reference

12 December 2020

Economic analysis of low-dose heparin vs the low-molecular-weight heparin enoxaparin for prevention of venous thromboembolism after colorectal surgery

1 reference

12 December 2020

Cost-effectiveness of low-molecular-weight heparin in the treatment of proximal deep vein thrombosis

1 reference

12 December 2020

Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin

1 reference

12 December 2020

Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. ENOXACAN Study Group

1 reference

12 December 2020

Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis

1 reference

12 December 2020

Long-term cost-effectiveness of low molecular weight heparin versus unfractionated heparin for the prophylaxis of venous thromboembolism in elective hip replacement

1 reference

12 December 2020

Pharmacoeconomic model of enoxaparin versus heparin for prevention of deep vein thrombosis after total hip replacement

1 reference

12 December 2020

The venous thrombotic risk in non-surgical patients: epidemiological data and efficacy/safety profile of a low-molecular-weight heparin (enoxaparin). The Prime Study Group

1 reference

12 December 2020

Chest pain centers: moving toward proactive acute coronary care

1 reference

12 December 2020

Cost effectiveness of a low-molecular-weight heparin in prolonged prophylaxis against deep vein thrombosis after total hip replacement

1 reference

12 December 2020

Proficient and cost-effective approaches for the prevention and treatment of venous thrombosis and thromboembolism

1 reference

12 December 2020

A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group

1 reference

12 December 2020

Comparison of the cost of preventing postoperative deep vein thrombosis with either unfractionated or low molecular weight heparin

1 reference

12 December 2020

Efficacy and cost of low-molecular-weight heparin compared with standard heparin for the prevention of deep vein thrombosis after total hip arthroplasty

1 reference

12 December 2020

Economic evaluation of enoxaparin sodium versus heparin in unstable angina. A French sub-study of the ESSENCE trial

1 reference

12 December 2020

Cost effectiveness of outpatient anticoagulant prophylaxis after total hip arthroplasty.

1 reference

12 December 2020

Economic Evaluation of Enoxaparin as Postdischarge Prophylaxis for Deep Vein Thrombosis (DVT) in Elective Hip Surgery

1 reference

12 December 2020

Costs of an emergency department-based accelerated diagnostic protocol vs hospitalization in patients with chest pain: a randomized controlled trial

1 reference

12 December 2020

A multicenter randomized double-blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in-patients bedridden for an acute medical illness. The Enoxaparin in Medicine Study Group

1 reference

12 December 2020

Patient outcomes and cost analysis associated with an outpatient deep venous thrombosis treatment program

1 reference

12 December 2020

Treatment of proximal vein thrombosis with subcutaneous low-molecular-weight heparin vs intravenous heparin. An economic perspective

1 reference

12 December 2020

Comparison of the efficacy and safety of low molecular weight heparins and unfractionated heparin in the initial treatment of deep venous thrombosis. An updated meta-analysis

1 reference

12 December 2020

Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial

1 reference

12 December 2020

Cost-effectiveness of enoxaparin versus warfarin prophylaxis against deep-vein thrombosis after total hip replacement

1 reference

12 December 2020

Low molecular weight versus unfractionated heparin. A clinical and economic appraisal

1 reference

12 December 2020

Deep venous thrombosis prophylaxis in trauma: cost analysis

1 reference

12 December 2020

Cost-effectiveness of prolonged administration of a low molecular weight heparin for the prevention of deep venous thrombosis following total hip replacement

1 reference

12 December 2020

Use of low molecular weight heparin in postangioplasty management

1 reference

12 December 2020

Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: one-year results of the ESSENCE Study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events

1 reference

12 December 2020

Care of patients with a low probability of acute myocardial infarction. Cost effectiveness of alternatives to coronary-care-unit admission

1 reference

12 December 2020

A comparative trial of a low molecular weight heparin (enoxaparin) versus standard heparin for the prophylaxis of postoperative deep vein thrombosis in general surgery

1 reference

12 December 2020

Clinical outcome and cost of hospital vs home treatment of proximal deep vein thrombosis with a low-molecular-weight heparin: the Vascular Midi-Pyrenees study

1 reference

12 December 2020

New-generation anticoagulants: the low molecular weight heparins

1 reference

12 December 2020

Cost-effectiveness analysis of enoxaparin versus unfractionated heparin for acute coronary syndromes. A Canadian hospital perspective

1 reference

12 December 2020

Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials

1 reference

12 December 2020

10.2165/00019053-200220040-00002

Identifiers

DOI

1 reference

Dimensions Publication ID

3 August 2017

1045788153

0 references

1 reference